For research use only
| Cat No. | ABC-TC0596 |
| Product Type | Rat Breast Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Rattus Norvegicus |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | AdenoCarcinoma |
| Product Code | LLC-WRC256; Walker/LLC-WRC 256; Walker-256; Walker-Ca.256; Walker 256; W256 |
The LLC-WRC 256 rat carcinoma cell line ideal for metastasis research, drug testing, and tumor biology studies in cancer progression models.
LLC-WRC 256 is a breast carcinosarcoma cell line established in 1952 from Walker 256 carcinosarcoma (originally breast carcinoma). The cells exhibit an epithelial-like morphology with a polygonal shape and grow adherently in monolayer cultures. Cytogenetically, LLC-WRC 256 displays a modal chromosome number of 41 (near diploid, 2n=42). LLC-WRC 256 is permissive to various viral infections, supporting the growth of herpes simplex virus, pseudorabies virus, and vaccinia virus. This characteristic makes it a valuable model for virology studies. It exhibits high tumorigenicity when implanted in nude mice but lacks documented metastatic behavior. Transcriptomic analyses have revealed phenotypic and molecular similarities between LLC-WRC 256 and human claudin-low breast tumors, a subtype characterized by low expression of cell-cell adhesion molecules and mesenchymal features. Functional studies indicate that cholesterol inhibits both proliferation and glutamine metabolism in these cells, while the compound Krest also effectively suppresses their growth.
| Product Code | LLC-WRC256; Walker/LLC-WRC 256; Walker-256; Walker-Ca.256; Walker 256; W256 |
| Species | Rattus Norvegicus |
| Cat.No | ABC-TC0596 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | AdenoCarcinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Rat Breast Cancer Cell Lines |
The LLC-WRC 256 cell line is extensively used in oncology for drug screening, mechanistic studies, and combination therapy development. It allows evaluation of anti-proliferative agents, oxidative stress markers, and tumor microenvironment modulation. This model supports viability assays, apoptosis detection, and cell cycle analysis, alongside molecular profiling of oncogenic pathway alterations. Particularly relevant to angiogenesis and solid tumor research, LLC-WRC 256 enables preclinical validation and high-throughput screening, bridging in vitro findings to in vivo applications.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
